Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Global Registry for Long-Term Follow-up of Patients Participating in Posoleucel Trials
2022-000763-45Phase 4Terminated
- Sponsor
- AlloVir, Inc.
- Start
- Jun 2022
- Modality
- Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of posoleucel in adenoviral infection, BK polyomavirus infection, progressive multifocal leukoencephalopathy (PML) and 3 more, sponsored by AlloVir, Inc. Primary endpoint: Incidence of adverse drug reactions (ADRs) related to posoleucel. Started Jun 2022; status: terminated.
02
Drugs
posoleucel
03
Conditions
adenoviral infectionBK polyomavirus infectionprogressive multifocal leukoencephalopathy (PML)human herpesvirus 6 infectionEpstein-Barr virus infection
Beyond the preview
Go deeper on 2022-000763-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000763-45.